Quarterly Commentary



Fund Managers: Richard Pease & James Milne

TM CRUX European Special Situations Fund

Fund performance was >> held back by some names that were de-rated, indiscriminately in our view, such as resilient chemical distributor Brenntag even though management raised guidance significantly during the quarter.

Market Update

Central bank policies were in the limelight as inflation continued to grind higher. The US Federal Reserve hiked interest rates in June, the biggest increase in decades. The ECB announced it would end bond-buying on 1 July and then raise rates. Absent of ECB support, Italian yields initially jumped with memories of the 2011 eurozone crisis recurring, but retreated somewhat as the ECB announced a plan to narrow the spread with German yields. European gas supplies remained a concern as Uniper warned about its predicament of being forced to replace ever-decreasing Russian supplies with sky-high spot prices elsewhere. Several US companies reported disappointing updates that could highlight a stretched consumer such as discount retailer Target and social network Snap on weak advertising income. Retailers started to issue profit warnings about weakening consumer demand and supply chain issues, such as Zalando in Europe. Against this background the TM CRUX European Special Situations Fund fell 11.5% compared to its IA Europe ex-UK which fell 9.6% over the guarter.*

*Source: FE 31.03.22-30.06.22 Bid-Bid in GBP. TR. net income re-invested.

Attribution Stock Level Q2 2022

Top 5 Contributors (%)	Bottom 5 Contributors (%)	
Prosus +0.58	Schneider -1.03	
Grifols +0.16	Aroundtown -0.85	
Novartis +0.10	Stroeer -0.71	
Sampo +0.09	Alphabet -0.61	
Novo Nordisk +0.08	Brenntag -0.57	

Source: Stat Pro

The fund underperformed due to a lack of exposure to energy and basic materials such as oil majors and steel mills which rallied in the wider market as well as being underweight in consumer staples and telecom stocks which rallied in the wider market. Some higher valued positions lost ground such as Givaudan, Bravida and SGS. Fund performance was held back by some names that were de-rated, indiscriminately in our view, such as resilient chemical distributor Brenntag even

Important Information

Please note the views, opinions and forecasts expressed in this document are based on CRUX's research and analysis at the time of publication. Before entering into an investment agreement in respect of an investment referred to in this document, you should consult your own professional and/or investment adviser. TM CRUX European Special Situations Fund (the 'Fund') is a sub-fund of TM CRUX OEIC (the 'Company'). The Company is an investment company with variable capital and is a UCITS Scheme. It is incorporated under the Open-Ended Investment Companies Regulations 2001 ('OEIC Regulations') in England and Wales under registry number IC001022. The Company is regulated by the FCA and was authorised on 10 December 2014. The FP CRUX European Special Situations Fund on 28

September 2019.
This information is only directed at persons residing in jurisdictions where the Company and its shares are authorised for distribution or where no such authorisation is required. Please read all scheme documents prior to investing. The KIID and Fund Prospectus and other documentation related to the Scheme, are available from the CRUX website. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested. If you invest through a third party provider you are advised to consult them directly as charges, performance and terms and conditions may differ materially than those shown on this document.



though management raised guidance significantly during the quarter. Some more cyclical stocks which lost ground such as electricals-maker Schneider and micro-chip manufacturers Infineon and STMicro.

Bright spots included Prosus which jumped as management will sell down its stake in Tencent to buyback shares in order to narrow the discount and Grifols advanced after reporting solid growth and recovering plasma collections. Diabetes maker Novo Nordisk surged on raising its growth guidance. Novartis advanced after it announced changes in its organisational structure and management leading to significant cost savings. Deutsche Borse advanced on an up-beat investor day.

Financials versus the Index

	Fund	Index
PE 2022	12x	12x
ROCE ex	29%	13%
Financials		
Net debt / EBITDA	0.6x	0.9x

Source: 30.06.22 CRUX/Bloomberg/ Datastream Index: Datastream 400 Index

Transactions

In terms of transactions, we sold Grifols after a recent rally, trimmed Trelleborg having performed well since selling its tyre division and took profits in Givaudan. We started a new position in Adidas which had nearly halved from its recent peak leaving it on a modest valuation based on historically low margins and significantly cheaper than US rival Nike despite buying back a significant portion of its shares; demand for its products tend to be fairly resilient in downturns and any inventory discounting has been more than factored into the share price. We disposed of our residual position in Just Eat Takeaway and disposed of our residual position in GN after a bounce. We topped up recent-purchase Allfunds, Stroer and Nordea.

In depth: Stabilus

The fund continues to have a strong focus on stocks with pricing power - ie companies that can fairly easily pass on inflation, which is particularly high at the moment. One such company is Stabilus. Stabilus's original product is the gas spring, and an easy application to describe is in a car, where a pair of them are used to keep the boot raised open. However gas springs are also found hundreds of other industrial "dampening" applications. The high barrier to entry is making millions of perfect gas spring per year for big customers like Toyota and VW. A fault is extremely costly for the car-makers as the recall costs quickly add up to tens of millions of pounds whereas the cost of the gas spring is a mere couple of pounds each. Moreover, over the decades, the other competitors have fallen by the wayside as they could not keep up with Stabilus's evolving technologies and expert manufacturing methods; this has left Stabilus with a near-monopoly. This is the perfect situation for pricing power, although Stabilus does often collaborate with customers to alter the design to keep price rises lower but maintaining their own margins.

Outlook

Equity markets have dropped back significantly since their highs, and we think that in many instances stock prices are now overly discounting a sharp recession and over-

Important Information

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures are sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 48 Pall Mall, London, SW1Y 5JG. It is authorised and regulated by the Financial Conduct Authority (FRN 623757). These figures refer to the past and past performance is not a reliable indicator of future results. The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.



looking the resilience of our companies' business models. In previous downturns, revenues of our holdings have been resilient; even when we pencil in a worst-case scenario, valuations still appear to be attractive. In most cases, management has improved the business resilience over the years, for example Schneider has a much higher proportion of recurring service sales than ever before. Moreover, balance sheets are very strong which can fund opportunistic acquisitions at bargain prices, which should cheer investors. Or indeed, our holdings could be the target themselves, particularly as private equity needs to put to work its recent large fund raisings.

Important Information

Please note: Due to rounding the figures in the holdings breakdown may not add up to 100%. Unless otherwise indicated all figures are sourced from Financial Express, Datastream, State Street and CRUX Asset Management Ltd. Third party data is believed to be reliable, but its completeness and accuracy is not guaranteed.

This document has been approved under Section 21 of the Financial Services and Markets Act 2000 by CRUX Asset Management Ltd. This document is issued by CRUX Asset Management Ltd which is registered in England and Wales (Company no. 08697189) and whose registered address is 48 Pall Mall, London, SW1Y 5JG. It is authorised and regulated by the Financial Conduct Authority (FRN 623757). These figures refer to the past and past performance is not a reliable indicator of future results. The Authorised Corporate Director is Thesis Unit Trust Management Limited, Exchange Building, St John's Street, Chichester, West Sussex, PO19 1UP. Authorised and regulated by the Financial Conduct Authority.